The role of angiogenesis in melanoma: Clinical treatments and future expectations
暂无分享,去创建一个
[1] J. Łuszczki,et al. Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines , 2022, International journal of molecular sciences.
[2] Douglas B. Johnson,et al. Clinical and genomic correlates of imatinib response in melanomas with KIT alterations , 2022, British Journal of Cancer.
[3] A. Carneiro,et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Xiao-lan Li,et al. Lactate promotes metastasis of normoxic colorectal cancer stem cells through PGC-1α-mediated oxidative phosphorylation , 2022, Cell Death & Disease.
[5] M. Hung,et al. Endothelial p130cas confers resistance to anti-angiogenesis therapy , 2022, Cell reports.
[6] B. Pothuri,et al. Appropriate Selection of PARP Inhibitors in Ovarian Cancer , 2022, Current Treatment Options in Oncology.
[7] Shin‐Yup Lee,et al. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer , 2022, Archives of Pharmacal Research.
[8] Emma S. Hathaway,et al. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors , 2022, Journal for ImmunoTherapy of Cancer.
[9] S. Goerdt,et al. Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment , 2022, Journal of translational medicine.
[10] K. Buder-Bakhaya,et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis , 2022, European Journal of Cancer.
[11] M. Cheung,et al. DEPDC1B Promotes Melanoma Angiogenesis and Metastasis through Sequestration of Ubiquitin Ligase CDC16 to Stabilize Secreted SCUBE3 , 2022, Advanced science.
[12] Yongdong Feng,et al. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer. , 2022, Future oncology.
[13] Lingdi Zhao,et al. Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma , 2020, The oncologist.
[14] A. Sebestyén,et al. The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues , 2021, Cancer and Metastasis Reviews.
[15] Jun Cao,et al. Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data , 2021, Investigational New Drugs.
[16] Xiu-qiong Fu,et al. Inhibition of Src/STAT3 signaling-mediated angiogenesis is involved in the anti-melanoma effects of dioscin. , 2021, Pharmacological research.
[17] Pengyun Li,et al. Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation , 2021, European Journal of Medicinal Chemistry.
[18] P. Caliceti,et al. Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment. , 2021, Journal of controlled release : official journal of the Controlled Release Society.
[19] S. Carroll,et al. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases , 2021, Cells.
[20] J. Encinar,et al. ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology , 2021, Journal of cellular and molecular medicine.
[21] P. Lacal,et al. VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody , 2021, Journal of Experimental & Clinical Cancer Research.
[22] D. Ribatti,et al. Nutraceuticals and their role in tumor angiogenesis. , 2021, Experimental cell research.
[23] J. Borén,et al. Intussusceptive angiogenesis in human metastatic malignant melanoma. , 2021, The American journal of pathology.
[24] Xiaosheng Wang,et al. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma , 2021, Computational and structural biotechnology journal.
[25] R. Verdijk,et al. In Uveal Melanoma, Angiopoietin-2 but Not Angiopoietin-1 Is Increased in High-Risk Tumors, Providing a Potential Druggable Target , 2021, Cancers.
[26] Nanxin Liu,et al. Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization. , 2021, Drug discovery today.
[27] Geunho Choi,et al. AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer , 2021, Frontiers in Pharmacology.
[28] M. Guida,et al. uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells , 2021, Oncology research.
[29] Jiake Xu,et al. Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma , 2021, Cell proliferation.
[30] C. Pereira,et al. Cell Fate Reprogramming in the Era of Cancer Immunotherapy , 2021, Frontiers in Immunology.
[31] Chia-Hao Huang,et al. Analysis of the Internal Hypoxic Environment in Solid Tumor Tissue Using a Folding Paper System. , 2021, ACS applied materials & interfaces.
[32] M. Ebrahimzadeh,et al. The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[33] L. Wagner,et al. Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors , 2021, Cancers.
[34] Yun Wang,et al. Advancing to the era of cancer immunotherapy , 2021, Cancer communications.
[35] C. Dehelean,et al. An In Vitro-In Vivo Evaluation of the Antiproliferative and Antiangiogenic Effect of Flavone Apigenin against SK-MEL-24 Human Melanoma Cell Line , 2021, Analytical cellular pathology.
[36] Zhijun Sun,et al. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges , 2021, Cancer communications.
[37] Wei Huang,et al. Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. , 2021, Experimental cell research.
[38] Takashi Watanabe. Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma , 2021, Cancers.
[39] B. C. Jena,et al. Active autophagy in cancer‐associated fibroblasts: Recent advances in understanding the novel mechanism of tumor progression and therapeutic response , 2021, Journal of cellular physiology.
[40] Qin Zhao,et al. Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[41] Tongchao Zhang,et al. Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study , 2021, Neoplasia.
[42] G. Drăghici,et al. Assessment of Betulinic Acid Cytotoxicity and Mitochondrial Metabolism Impairment in a Human Melanoma Cell Line , 2021, International journal of molecular sciences.
[43] J. Rysz,et al. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer , 2021, International journal of molecular sciences.
[44] Haibin Xia,et al. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy. , 2021, Cancer letters.
[45] W. Miller,et al. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit , 2021, Molecular Cancer Research.
[46] Ning Zhang,et al. Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. , 2021, Journal of integrative medicine.
[47] M. Zhang,et al. Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. , 2021, Cancer letters.
[48] M. Apte,et al. Angiopoietin inhibitors: A review on targeting tumor angiogenesis. , 2021, European journal of pharmacology.
[49] D. Del Bufalo,et al. Bcl-xL: A Focus on Melanoma Pathobiology , 2021, International journal of molecular sciences.
[50] Douglas B. Johnson,et al. Defining and Targeting BRAF Mutations in Solid Tumors , 2021, Current Treatment Options in Oncology.
[51] M. Unno,et al. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors , 2021, Medical Oncology.
[52] Lisong Shen,et al. Extracellular vesicle‐mediated regulation of tumor angiogenesis— implications for anti‐angiogenesis therapy , 2021, Journal of cellular and molecular medicine.
[53] Li Zhou,et al. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] U. Höpken,et al. Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth , 2020, Frontiers in Immunology.
[55] H. Gelderblom,et al. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib , 2020, Expert opinion on investigational drugs.
[56] Suzie Chen,et al. Overcoming Immune Evasion in Melanoma , 2020, International journal of molecular sciences.
[57] Y. Bang,et al. Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial , 2020, Clinical Cancer Research.
[58] J. Ji,et al. Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression , 2020, Journal of cellular and molecular medicine.
[59] M. Moncrieff,et al. Mitochondrial oxidative phosphorylation in cutaneous melanoma , 2020, British journal of cancer.
[60] R. Smolarczyk,et al. Invited submission by the editor marek los vascular disrupting agents in cancer therapy. , 2020, European journal of pharmacology.
[61] Fenghua Wang,et al. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study , 2020, Investigational New Drugs.
[62] F. Amant,et al. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[63] T. Rodrigues,et al. Therapeutic potential of targeting mitochondrial dynamics in cancer. , 2020, Biochemical pharmacology.
[64] Ken Kato,et al. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503) , 2020, ESMO Open.
[65] J. Nova,et al. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population , 2020, BioMed research international.
[66] Desong Yang,et al. Parthenolide Inhibits Angiogenesis in Esophageal Squamous Cell Carcinoma Through Suppression of VEGF , 2020, OncoTargets and therapy.
[67] P. Rutkowski,et al. Targeted Therapy in Melanoma and Mechanisms of Resistance , 2020, International journal of molecular sciences.
[68] L. Filippi,et al. Current Therapies and New Targets to Fight Melanoma: A Promising Role for the β3-Adrenoreceptor , 2020, Cancers.
[69] Suping Li,et al. Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells , 2020, Acta Pharmacologica Sinica.
[70] Xiaoling Zhang,et al. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling , 2020, Cancer biology & medicine.
[71] E. Licărete,et al. Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment , 2020, International journal of molecular sciences.
[72] Yiyan Lei,et al. HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling , 2020, Theranostics.
[73] R. Motzer,et al. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] G. Lenz,et al. Lymphoma angiogenesis is orchestrated by noncanonical signaling pathways. , 2020, Cancer research.
[75] Anubhab Mukherjee,et al. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer , 2020, International journal of molecular sciences.
[76] W. Ciszewski,et al. Endothelial Cells in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.
[77] M. Aghi,et al. Autophagy as a Mechanism for Anti-Angiogenic Therapy Resistance. , 2020, Seminars in cancer biology.
[78] A. Reynolds,et al. Vessel co-option and resistance to anti-angiogenic therapy , 2019, Angiogenesis.
[79] M. Barbaccia,et al. Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib , 2019, Journal of cellular and molecular medicine.
[80] M. Mita,et al. PARP Inhibition in Cancer: An Update on Clinical Development , 2019, Targeted Oncology.
[81] A. Carrato,et al. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms , 2019, International journal of molecular sciences.
[82] Xiaoming Wang,et al. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway. , 2019, European journal of pharmacology.
[83] H. Hollema,et al. Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers , 2019, Pathology & Oncology Research.
[84] K. Flaherty,et al. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] Xuri Li,et al. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets. , 2019, Pharmacological research.
[86] M. R. Ruocco,et al. Metabolic flexibility in melanoma: a potential therapeutic target. , 2019, Seminars in cancer biology.
[87] G. Jour,et al. Role of angiogenesis in melanoma progression: update on key angiogenic mechanisms and other associated components. , 2019, Seminars in cancer biology.
[88] P. Delrio,et al. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment , 2019, Cancer management and research.
[89] M. Caligiuri,et al. Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[90] M. Weinstock,et al. Cutaneous nevi and risk of melanoma death in women and men: A prospective study , 2019, Journal of the American Academy of Dermatology.
[91] Yunjian Zhang,et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway , 2019, Journal of experimental & clinical cancer research : CR.
[92] I. Zupkó,et al. A Comprehensive Assessment of Apigenin as an Antiproliferative, Proapoptotic, Antiangiogenic and Immunomodulatory Phytocompound , 2019, Nutrients.
[93] M. Haris,et al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance , 2019, Molecular Cancer.
[94] H. Moch,et al. Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis , 2019, Journal of cutaneous pathology.
[95] E. Thiele,et al. Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis , 2019, Orphanet Journal of Rare Diseases.
[96] S. Aamdal,et al. Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma , 2019, Clinical and experimental immunology.
[97] A. M. Troncoso,et al. Inhibition of VEGFR-2 Phosphorylation and Effects on Downstream Signaling Pathways in Cultivated Human Endothelial Cells by Stilbenes from Vitis Spp. , 2019, Journal of Agricultural and Food Chemistry.
[98] Anping Li,et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy , 2019, Journal of Hematology & Oncology.
[99] M. Zeman,et al. Synergic effects of inhibition of glycolysis and multikinase receptor signalling on proliferation and migration of endothelial cells. , 2019, General physiology and biophysics.
[100] R. Raman,et al. Anti-angiogenic effect of adiponectin in human primary microvascular and macrovascular endothelial cells. , 2019, Microvascular research.
[101] H. Pan,et al. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials , 2019, Journal of Cancer.
[102] B. Baradaran,et al. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis , 2018, Journal of cellular physiology.
[103] L. Farahmand,et al. Challenges facing antiangiogenesis therapy: The significant role of hypoxia‐inducible factor and MET in development of resistance to anti‐vascular endothelial growth factor‐targeted therapies , 2018, Journal of cellular physiology.
[104] E. White,et al. Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). , 2019, Cancer treatment and research communications.
[105] J. Johansson,et al. Consumption of whole grain/bran rye instead of refined wheat decrease concentrations of TNF-R2, e-selectin, and endostatin in an exploratory study in men with prostate cancer. , 2019, Clinical nutrition.
[106] Yan Wu,et al. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF‐1&agr; nuclear translocation , 2018, International immunopharmacology.
[107] I. Tempera,et al. Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1 , 2018, PLoS pathogens.
[108] L. A. Al Kury,et al. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[109] J. Kirkwood,et al. NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma , 2018, Cancer.
[110] T. Dragovich,et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma , 2018, OncoTargets and therapy.
[111] P. Lacal,et al. Therapeutic implication of vascular endothelial growth factor receptor‐1 (VEGFR‐1) targeting in cancer cells and tumor microenvironment by competitive and non‐competitive inhibitors , 2018, Pharmacological research.
[112] N. Li,et al. Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer Cells , 2018, Journal of Cancer.
[113] E. Brambilla,et al. VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop , 2018, Oncogene.
[114] Juke Zheng,et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1a regulates heart regeneration by promoting the survival of cardiac stem cell. , 2018, Biochemical and biophysical research communications.
[115] F. Zhou,et al. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. , 2018, European journal of cancer.
[116] V. Servois,et al. Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases , 2018, The journal of pathology. Clinical research.
[117] P. Lorigan,et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial , 2018, British Journal of Cancer.
[118] P. Dziewulski,et al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[119] D. Teti,et al. Genistein reduces proliferation of EP3‐expressing melanoma cells through inhibition of PGE2‐induced IL‐8 expression , 2018, International immunopharmacology.
[120] K. Osann,et al. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma , 2018, Cancer Chemotherapy and Pharmacology.
[121] R. Sullivan,et al. Management of Metastatic Melanoma in 2018 , 2018, JAMA oncology.
[122] Y. Huan,et al. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (CBCRT01) , 2018, International journal of cancer.
[123] R. Pearson,et al. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance , 2018, International journal of cancer.
[124] Yibo Tang,et al. Endostatin gene therapy delivered by attenuated Salmonellatyphimurium in murine tumor models , 2018, Cancer Gene Therapy.
[125] Paolo A Ascierto,et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.
[126] F. Howe,et al. Assessment of the direct effects of DDAH I on tumour angiogenesis in vivo , 2018, Angiogenesis.
[127] Peijun Liu,et al. Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF‐1α‐induced pro‐angiogenic factor , 2018, Cancer science.
[128] R. Giavazzi,et al. Anti-angiogenesis for cancer: Current status and prospects. , 2018, Thrombosis research.
[129] Li-ping Yang,et al. A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma , 2018, Cancer biology & therapy.
[130] G. Balistreri,et al. Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation , 2018, eLife.
[131] W. Sperl,et al. Melanoma tumors exhibit a variable but distinct metabolic signature , 2018, Experimental dermatology.
[132] J. Steinbach,et al. Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma , 2018, Journal of neurochemistry.
[133] Yu-Ying He,et al. Mechanisms and prevention of UV‐induced melanoma , 2018, Photodermatology, photoimmunology & photomedicine.
[134] Zheng Liu,et al. Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway , 2017, Oncology letters.
[135] A. Tiwari,et al. MicroRNA Key to Angiogenesis Regulation: MiRNA Biology and Therapy. , 2017, Current cancer drug targets.
[136] J. Lawler,et al. Integration of pro- and anti-angiogenic signals by endothelial cells , 2018, Journal of Cell Communication and Signaling.
[137] D. Schadendorf,et al. A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma , 2018, Investigational New Drugs.
[138] R. Milner,et al. Chronic mild hypoxia promotes profound vascular remodeling in spinal cord blood vessels, preferentially in white matter, via an α5β1 integrin-mediated mechanism , 2018, Angiogenesis.
[139] J. Ledermann,et al. Front-line therapy of advanced ovarian cancer: new approaches , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[140] A. Laurenzana,et al. uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells , 2017, International journal of cancer.
[141] Shan Wang,et al. Endostatin sensitizes p53‐deficient non‐small‐cell lung cancer to genotoxic chemotherapy by targeting DNA‐dependent protein kinase catalytic subunit , 2017, The Journal of pathology.
[142] T. Petrova,et al. Microenvironmental regulation of tumour angiogenesis , 2017, Nature Reviews Cancer.
[143] B. Larrivée,et al. Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.
[144] Bruno Larrivée,et al. Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.
[145] Santoshi Muppala,et al. Thrombospondin-4 mediates TGF-β-induced angiogenesis , 2017, Oncogene.
[146] R. Dummer,et al. Developments in targeted therapy in melanoma. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[147] R. Dummer,et al. The safety of anti PD-1 therapeutics for the treatment of melanoma , 2017, Expert opinion on drug safety.
[148] C. Balch,et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[149] O. Casanovas,et al. Angiogenesis and Metabolism: Entwined for Therapy Resistance. , 2017, Trends in cancer.
[150] A. Andiappan,et al. Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice , 2016, Scientific Reports.
[151] R. Dummer,et al. An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel , 2016, The British journal of dermatology.
[152] Qingshun Zhao,et al. Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor‐α mRNA via decreasing nuclear–cytoplasmic translocation of RNA‐binding protein HuR , 2016, Molecular carcinogenesis.
[153] E. Smyth,et al. Immunotherapy for Gastroesophageal Cancer , 2016, Journal of clinical medicine.
[154] V. Servois,et al. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study , 2016, British Journal of Cancer.
[155] J. Carles,et al. Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients , 2016, Cell reports.
[156] Lixia Xu,et al. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib. , 2016, Cancer letters.
[157] H. Kleinman,et al. Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways , 2016, Scientific Reports.
[158] G. Christofori,et al. VEGF receptor-2-specific signaling mediated by VEGF-E induces hemangioma-like lesions in normal and in malignant tissue , 2016, Angiogenesis.
[159] F. Roviello,et al. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. , 2016, Cancer letters.
[160] G. Jour,et al. Angiogenesis in melanoma: an update with a focus on current targeted therapies , 2016, Journal of Clinical Pathology.
[161] A. D. Van den Abbeele,et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma , 2015, Cancer.
[162] S. Katiyar,et al. Silymarin inhibits melanoma cell growth both in vitro and in vivo by targeting cell cycle regulators, angiogenic biomarkers and induction of apoptosis , 2015, Molecular carcinogenesis.
[163] F. Hodi,et al. Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data , 2015, Front. Oncol..
[164] T. Salo,et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment. , 2015, Experimental cell research.
[165] J. Nemunaitis,et al. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma , 2015, Clinical Cancer Research.
[166] J. Tímár,et al. Mechanism of tumour vascularization in experimental lung metastases , 2015, The Journal of pathology.
[167] B. Dréno,et al. Comparative analysis of BRAF, NRAS and c‐KIT mutation status between tumor tissues and autologous tumor cell‐lines of stage III/IV melanoma , 2015, Experimental dermatology.
[168] S. Carmichael,et al. Angiotropism, Pericytic Mimicry and Extravascular Migratory Metastasis in Melanoma: An Alternative to Intravascular Cancer Dissemination , 2014, Cancer Microenvironment.
[169] J. Wolchok,et al. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. , 2014, European journal of cancer.
[170] D. Neri,et al. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy , 2014, Cancer Immunology, Immunotherapy.
[171] Cizhong Jiang,et al. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. , 2014, Cancer letters.
[172] A. D. Van den Abbeele,et al. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.
[173] A. Sood,et al. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches , 2014, Cancer and Metastasis Reviews.
[174] Masao Iwata,et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. , 2013, Cancer letters.
[175] Ping Yang,et al. Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells , 2013, Anti-cancer drugs.
[176] T. Kume,et al. FoxC1-dependent regulation of vascular endothelial growth factor signaling in corneal avascularity. , 2013, Trends in cardiovascular medicine.
[177] S. Okolicsanyi,et al. Cyclic AMP/PKA‐dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin‐2 defective mice treated with sorafenib , 2012, Hepatology.
[178] M. Mukherji,et al. Honokiol inhibits HIF pathway and hypoxia-induced expression of histone lysine demethylases. , 2012, Biochemical and biophysical research communications.
[179] S. Puig,et al. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway , 2012, International journal of cancer.
[180] M. Shibuya. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. , 2011, Genes & cancer.
[181] Y. Okada,et al. Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production , 2011, British Journal of Cancer.
[182] Yang Zhang,et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[183] Jeeyun Lee,et al. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia , 2011, Melanoma research.
[184] A. Suttle,et al. An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors , 2010, Clinical pharmacology and therapeutics.
[185] Daniel B. Neill,et al. Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors , 2010, Clinical Cancer Research.
[186] Rakesh K. Singh,et al. CXCL8 and its cognate receptors in melanoma progression and metastasis. , 2010, Future oncology.
[187] J. Gallo,et al. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. , 2009, Neuro-oncology.
[188] J. Kirkwood,et al. Management of metastatic melanoma. , 2007, Seminars in oncology.
[189] C. Leonetti,et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. , 2007, European journal of cancer.
[190] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[191] Qinghua Zhou,et al. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. , 2005, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[192] A. Figueras,et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. , 2004, The Journal of investigative dermatology.
[193] L. Akslen,et al. Angiogenesis is prognostically important in vertical growth phase melanomas. , 1999, International journal of oncology.
[194] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[195] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[196] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[197] T. Fears,et al. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. , 1977, American journal of epidemiology.
[198] P. Shubik,et al. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. , 1966, Laboratory investigation; a journal of technical methods and pathology.
[199] Michael Schwenk,et al. Tumor , 1828, The London medical and physical journal.